印度的Hetero Healthcare和Enzene Biosciences公司推出了价格实惠的生物类似药物Perzea,用于治疗HER2阳性乳腺癌. Hetero Healthcare and Enzene Biosciences launch affordable biosimilar Perzea for HER2-positive breast cancer in India.

与Enzene Biosciences合作的血清保健公司在印度推出了Perzea, 这是一种负担得起的生物,类似于Pertuzumab, 一种治疗HER2-阳性乳腺癌的治疗。 Hetero Healthcare, with Enzene Biosciences, has launched Perzea, an affordable biosimilar to Pertuzumab, a treatment for HER2-positive breast cancer, in India. 该药物使用连续制造技术,满足全球质量标准,同时降低成本,帮助更多的病人获得关键的癌症护理。 The drug, made using continuous manufacturing technology, meets global quality standards while lowering costs, helping more patients access critical cancer care. 这场发射支持印度的公平保健目标,并借鉴了赫特罗提供低成本肿瘤治疗的历史。 The launch supports India’s goal of equitable healthcare and builds on Hetero’s history of providing low-cost oncology treatments.